Advertisement
"The Chinese government plans to increase subsidies for the rural medicalinsurance system, which we believe will be a huge potential market for ourproducts," said Mr. Yan-Qing Liu, Chairman and CEO of China Sky One Medical."These four new drugs address a number of relatively common diseases in ruralChina and we have already created a sales force aimed at the rural market. Weexpect to launch these new drugs in the second quarter of 2009 and willprovide a detailed sales estimate shortly."
Advertisement
About China Sky One Medical, Inc.
China Sky One Medical, Inc., a Nevada corporation, is a holding company.The Company engages in the manufacturing, marketing and distribution ofpharmaceutical, medicinal and diagnostic products. Through its wholly-ownedsubsidiaries, Harbin Tian Di Ren Medical Science and Technology Company("TDR"), Harbin First Bio-Engineering Company Limited ("First"), HeilongjiangTianlong Pharmaceutical, Inc. ("Tianlong") and Peng Lai Jin Chuang CompanyPharmaceutical Company ("Jin Chuang") the Company manufactures and distributesover-the-counter pharmaceutical products, which make up its major revenuesource. For more information, visit http://www.skyonemedical.com .
Safe Harbor Statement
Certain of the statements made in the press release constituteforward-looking statements within the meaning of the Private SecuritiesLitigation Reform Act of 1995. These statements can be identified by the useof forward- looking terminology such as "believe," "expect," "may," "will,""should," "project," "plan," "seek," "intend," or "anticipate" or the negativethereof or comparable terminology. Such statements typically involve risks anduncertainties and may include financial projections or information regardingour future plans, objectives or performance. Actual results could differmaterially from the expectations reflected in such forward-looking statementsas a result of a variety of factors, including the risks associated with theeffect of changing economic conditions in The People's Republic of China,variations in cash flow, reliance on collaborative retail partners and on newproduct development, variations in new product development, risks associatedwith rapid technological change, and the potential of introduced or undetectedflaws and defects in products, and other risk factors detailed in reportsfiled with the Securities and Exchange Commission from time to time.-- Dithranol ointment is intended to treat different types of psoriasis, such as plaque psoriasis, guttate psoriasis and hypertrophy psoriasis; -- Antipruritic tincture is intended to soothe itchy skin and reduce inflammation; it can also be used for infection and bruises; -- Antiasthma cream is intended to treat cough, asthma and chronic bronchitis; and -- Levofloxacin Lactate injection is used to treat moderate to severe respiratory system, urinary system, and digestive system infections, as well as soft skin tissue infections. It can also treat septicemia, urethritis, and cervicitis.
SOURCE China Sky One Medical, Inc.
